Inpharma

Rotavirus vaccines: universal access soon?
pp. 2-2(1)

How to handle an avian influenza pandemic?
pp. 3-3(1)

New rules to govern clinical trials in India?
pp. 3-3(1)

The US FDA has proposed a rule designed to simplify premarket review and regulation of combination products.
pp. 3-3(1)

The antitumour efficacy of anti-EGFR monoclonal antibody 806 will be investigated in early-phase clinical trials
pp. 3-3(1)

Consensus guidelines for the treatment of acute decompensated heart failure (HF) in the emergency-department setting of US GPO hospitals have been developed
pp. 4-4(1)

A coffee a day keeps neurodegeneration away?
pp. 4-4(1)

Prevention and treatment of vascular dementia
pp. 4-4(1)

New paediatric influenza vaccination recommendations have been published by the US Centers for Disease Control and Prevention
pp. 4-4(1)

News from the 16th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy
pp. 5-6(2)

Triptan use in France not currently ideal
pp. 6-6(1)

Sildenafil safely improves QOL in men with moderate heart failure?
pp. 6-6(1)

Inhaled corticosteroids worth it in patients with severe COPD
pp. 7-7(1)

One-dose immunisation best for meningococcal group C infections
pp. 7-7(1)

The growing number of patients with advanced liver disease will fuel a rise in the hepatitis C virus (HCV) therapy market to $US10 billion in 2013
pp. 7-7(1)

Stem-cell transplant from unrelated cord blood for Hurler's syndrome
pp. 8-8(1)

The investigational polymer therapy, tolevamer, shows promise in the treatment of Clostridium difficile-associated diarrhoea
pp. 8-8(1)

The investigational drug, pegaptanib [Macugen], showed positive visual and anatomical outcomes for diabetic macular oedema
pp. 8-8(1)

Recently released pharmacokinetic data shows that the antisense drug, AVI 4020, successfully crosses the blood-brain barrier.
pp. 8-8(1)

Daclizumab improves control of chronic persistent asthma
pp. 9-10(2)

Do stem cells really repair the heart?
pp. 10-10(1)

Intravesical administration of bio-adhesive paclitaxel microspheres appears promising in bladder cancer
pp. 10-10(1)

Met-enkephalin treatment safe and useful for pancreatic cancer?
pp. 10-10(1)

Oxcarbazepine as adjunctive therapy is effective in the treatment of patients with bipolar disorders
pp. 11-11(1)

Potential HIV treatment that targets host-cell pathway
pp. 11-11(1)

BB 83698 active against streptococci and Moraxella catarrhalis
pp. 11-11(1)

News from the 53rd Annual Scientific Session of the ACC
pp. 12-14(3)

Improving management of head and neck cancer
pp. 14-14(1)

H. pylori eradication treatment: no net effect on GERD
pp. 14-14(1)

Ibandronic acid beneficial in metastatic bone disease
pp. 15-15(1)

BCG vaccine: long-term protection against TB
pp. 15-15(1)

Infliximab improves physical functioning in RA
pp. 15-15(1)

Lipid-lowering therapy beneficial in the perioperative period
pp. 16-16(1)

Nelfinavir vs ritonavir in advanced HIV disease
pp. 16-16(1)

Discontinuation of hormone therapy leads to rapid loss of hip fracture protection
pp. 16-16(1)

Methylphenidate appears to be superior to atomoxetine in children with attention deficit hyperactivity disorder
pp. 16-16(1)

Quinapril long-term benefits after coronary intervention
pp. 17-17(1)

Nimodipine is effective in the treatment of primary thunderclap headache
pp. 17-17(1)

Imatinib was used successfully to treat hepatocellular carcinoma
pp. 17-17(1)

Low-dose risperidone may be a safe and effective treatment for patients suffering from delirium
pp. 17-17(1)

Single oral doses of risperidone plus lorazepam are as effective as IM haloperidol plus IM lorazepam for the acute treatment of psychotic agitation
pp. 17-17(1)

Arginine has no effects on neointimal proliferation in patients undergoing coronary stenting
pp. 18-18(1)

Clopidogrel + aspirin for stroke prevention after CEA?
pp. 18-18(1)

Clopidogrel before PCI: anti-inflammatory benefits
pp. 18-18(1)

Myocardial vasodilation improved by simvastatin but not pravastatin
pp. 19-19(1)

Standard dose of clopidogrel inadequate in PCI
pp. 19-19(1)

Chromium/biotin supplementation improves coronary risk factors in patients with type 2 diabetes mellitus
pp. 19-19(1)

Represcription of penicillin after allergic-like events common
pp. 20-20(1)

EMEA finalises review of paroxetine-containing medicines
pp. 20-20(1)

Polio eradication threatened by vaccine-associated poliovirus
pp. 20-20(1)

For the treatment of drug-induced psychosis in Parkinson's disease (PD) "preliminary experience with aripiprazole is mixed
pp. 20-20(1)

GlaxoSmithKline has been granted priority review status in Japan for adefovir dipivoxil [Hepsera; licensed from Gilead Sciences]
pp. 21-21(1)

AstraZeneca has launched fulvestrant [Faslodex] in the UK
pp. 21-21(1)

Following an independent review of the UK Yellow Card Scheme, the MHRA is to pilot patient reporting
pp. 21-21(1)

Four-fold elevation in mortality with pituitary-derived GH
pp. 21-21(1)

EU regulatory news
pp. 21-21(1)

Health Canada has approved a new two-dose regimen of Meningococcal group C conjugate vaccine [NeisVac-C; Shire Biologics]
pp. 21-21(1)

The oral adsorbent, AST 120 [Kremezin; Kureha Chemical], has been approved in South Korea
pp. 22-22(1)

US product launches
pp. 22-22(1)

US product approvals
pp. 22-22(1)

Other regulatory news from the US
pp. 22-22(1)

Bentley Pharmaceuticals has received approval to market a branded and a generic version of ibuprofen paediatric suspension in Spain.
pp. 22-22(1)

Verteporfin [Visudyne; Novartis] has been launched in Japan
pp. 22-22(1)

Ofloxacin otic solution 0.3% [Floxin Otic Singles] has been launched in the US by Daiichi Pharmaceutical.
pp. 22-22(1)

Product Introductions
pp. 23-23(1)